As a division, DCTD staff members and their extramural colleagues are exploring various routes toward discovery, development, and delivery of cancer therapeutics. The fundamental objective is to find and develop more interventions tailored to the specific characteristics of a patient’s cancer. The following summaries highlight some of the division’s recent accomplishments in the areas of clinical and translational cancer research.
- Changes to Early and Late Translational Research at NCI
- Evaluating the Predictive and Prognostic Value of Molecular Markers to the Epidermal Growth Factor Receptor in a Phase III Study of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
- Phase 0 Imaging Agent Study
- The NCI Experimental Therapeutics Program (NExT)
- More Phase 0 Activities
About the Director
James H. Doroshow, M.D., FACP, has been the Director of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), since 2004. He is responsible for integrating the activities of DCTD with NCI’s other divisions and offices, as well as extramural scientists and clinicians, patient advocates, and professional cancer organizations. More…